Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America

Clinical Infectious Diseases

Volumn 59, Issue 2, 2014, Pages

  Stevens, Dennis L ^a   Bisno, Alan L ^b   Chambers, Henry F ^c   Dellinger, E Patchen ^d   Goldstein, Ellie J C ^e   Gorbach, Sherwood L ^f   Hirschmann, Jan V ^g   Kaplan, Sheldon L ^h   Montoya, Jose G ⁱ   Wade, James C ^j  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b Miami Veterans Affairs Healthcare System   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f TUFTS UNIVERSITY   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j GEISINGER HEALTH SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CARBAPENEM; CEFALEXIN; CEFAZOLIN; CEFTAROLINE; CHLORHEXIDINE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DICLOXACILLIN; DOXYCYCLINE; ERYTHROMYCIN; LINEZOLID; MINOCYCLINE; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G POTASSIUM; PENICILLIN V; PENICILLIN V POTASSIUM; PIPERACILLIN PLUS TAZOBACTAM; PSEUDOMONIC ACID; RETAPAMULIN; SULTAMICILLIN; TETANUS TOXOID; UNINDEXED DRUG; VANCOMYCIN;

AEROMONAS HYDROPHILA; ALGORITHM; ANTIBIOTIC THERAPY; APPARENT LIFE THREATENING EVENT; BACTERIAL SKIN DISEASE; CANCER PATIENT; CARBUNCLE; CELLULAR IMMUNODEFICIENCY; CLINICAL EVALUATION; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; DOG BITE; ECTHYMA; EPIDERMOID CYST; FURUNCULOSIS; HUMAN; IMMUNOCOMPROMISED PATIENT; IMPETIGO; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NECROTIZING FASCIITIS; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; SUPPURATION; URETHRA STRICTURE; URINARY TRACT INFECTION; WOUND CLOSURE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; UNITED STATES;

HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; UNITED STATES;

EID: 84903947423     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu296     Document Type: Review

References (247)

1. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008; 336:1049-51.
2. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6. (Pubitemid 351632017)
3. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ 2008; 336:995-8. (Pubitemid 351656090)
4. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008; 337:a744.
5. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009; 15:1516-8.
6. Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-Associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008; 51:291-8.
7. Pallin DJ, Espinola JA, Leung DY, Hooper DC, Camargo CA Jr. Epidemiology of dermatitis and skin infections in United States physicians' offices, 1993-2005. Clin Infect Dis. 2009; 49:901-7.
8. Field MJ, Lohr KN; Institute of Medicine. Committee to Advise the Public Health Service on Clinical Practice Guidelines, United States. Department of Health and Human Services. Clinical practice guidelines: Directions for a new program. Washington, DC: National Academy Press, 1990.
9. Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources use into grading recommendations. BMJ 2008; 336:1170-3. (Pubitemid 351809277)
10. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336:1106-10. (Pubitemid 351731739)
11. Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012; 54:e72-e112.
12. Hirschmann JV. Impetigo: Etiology and therapy. Curr Clin Top Infect Dis. 2002; 22:42-51.
13. Durupt F, Mayor L, Bes M, et al. Prevalence of Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo. Br J Dermatol 2007; 157:1161-7. (Pubitemid 350115678)
14. Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: Randomized double-blind multicentre placebo-controlled trial. Br J Dermatol 2008; 158:1077-82. (Pubitemid 351521449)
15. Wasserzug O, Valinsky L, Klement E, et al. A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes. Clin Infect Dis. 2009; 48:1213-9.
16. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
17. Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-Acquired skin abscesses in the pediatric patient. Ann Emerg Med. 2010; 55:401-7.
18. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-Acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51:4044-8. (Pubitemid 350057804)
19. Diven DG, Dozier SE, Meyer DJ, Smith EB. Bacteriology of inflamed and uninflamed epidermal inclusion cysts. Arch Dermatol 1998; 134:49-51. (Pubitemid 28087113)
20. Gaspari RJ, Resop D, Mendoza M, Kang T, Blehar D. A randomized controlled trial of incision and drainage versus ultrasonographically guided needle aspiration for skin abscesses and the effect of methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2011; 57:483-91. e1.
21. Macfie J, Harvey J. The treatment of acute superficial abscesses: A prospective clinical trial. Br J Surg 1977; 64:264-6. (Pubitemid 8075132)
22. Llera JL, Levy RC. Treatment of cutaneous abscess: A double-blind clinical study. Ann Emerg Med. 1985; 14:15-9. (Pubitemid 15161258)
23. O'Malley GF, Dominici P, Giraldo P, et al. Routine packing of simple cutaneous abscesses is painful and probably unnecessary. Acad Emerg Med 2009; 16:470-3.
24. Rutherford WH, Hart D, Calderwood JW, Merrett JD. Antibiotics in surgical treatment of septic lesions. Lancet 1970; 1:1077-80.
25. Schmitz GR, Bruner D, Pitotti R, et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-Associated methicillin-resistant Staphylococcus aureus infection. Ann Emerg Med. 2010; 56:283-7.
26. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: A comprehensive review. J Am Acad Dermatol 2009; 60:539-61; quiz 62-3.
27. Humphries AE, Duncan JE. Evaluation and management of pilonidal disease. Surg Clin North Am 2010; 90:113-24, table of contents.
28. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA 1988; 260:2682-5. (Pubitemid 18261979)
29. Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 1996; 156:1109-12. (Pubitemid 26158068)
30. Rahimian J, Khan R, LaScalea KA. Does nasal colonization or mupirocin treatment affect recurrence of methicillin-resistant Staphylococcus aureus skin and skin structure infections? Infect Control Hosp Epidemiol 2007; 28:1415-6. (Pubitemid 351412096)
31. Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-Associated methicillin- resistant Staphylococcus aureus strains in soldiers: A cluster randomized controlled trial. Antimicrob Agents Chemother 2007; 51:3591-8. (Pubitemid 47519348)
32. Whitman TJ, Herlihy RK, Schlett CD, et al. Chlorhexidine-impregnated cloths to prevent skin and soft-tissue infection in Marine recruits: A cluster-randomized, double-blind, controlled effectiveness trial. Infect Control Hosp Epidemiol 2010; 31:1207-15.
33. Wiese-Posselt M, Heuck D, Draeger A, et al. Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillinsusceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005. Clin Infect Dis. 2007; 44:e88-95.
34. Fritz SA, Hogan PG, Hayek G, et al. Household versus individual approaches to eradication of community-Associated Staphylococcus aureus in children: A randomized trial. Clin Infect Dis. 2012; 54:743-51.
35. Hirschmann JV, Raugi GJ. Lower limb cellulitis and its mimics: Part I. Lower limb cellulitis. J Am Acad Dermatol 2012; 67:163 e1-12; quiz 75-6.
36. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): Case-control study. BMJ 1999; 318:1591-4. (Pubitemid 29267772)
37. Bjornsdottir S, Gottfredsson M, Thorisdottir AS, et al. Risk factors for acute cellulitis of the lower limb: A prospective case-control study. Clin Infect Dis. 2005; 41:1416-22. (Pubitemid 41579982)
38. Perl B, Gottehrer NP, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis. 1999; 29:1483-8. (Pubitemid 30022745)
39. HookEW 3rd, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986; 146:295-7. (Pubitemid 16018547)
40. Sachs MK. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 1990; 150:1907-12. (Pubitemid 20316536)
41. Leppard BJ, Seal DV, Colman G, Hallas G. The value of bacteriology and serology in the diagnosis of cellulitis and erysipelas. Br J Dermatol 1985; 112:559-67. (Pubitemid 15060995)
42. Kielhofner MA, Brown B, Dall L. Influence of underlying disease process on the utility of cellulitis needle aspirates. Arch Intern Med 1988; 148:2451-2.
43. Sigurdsson AF, Gudmundsson S. The etiology of bacterial cellulitis as determined by fine-needle aspiration. Scand J Infect Dis. 1989; 21:537-42. (Pubitemid 19263005)
44. Newell PM, Norden CW. Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults. J Clin Microbiol 1988; 26:401-4. (Pubitemid 18062089)
45. Lebre C, Girard-Pipau F, Roujeau JC, Revuz J, Saiag P, Chosidow O. Value of fine-needle aspiration in infectious cellulitis. Arch Dermatol 1996; 132:842-3. (Pubitemid 26238885)
46. Lutomski DM, Trott AT, Runyon JM, Miyagawa CI, Staneck JL, Rivera JO. Microbiology of adult cellulitis. J Fam Pract 1988; 26:45-8. (Pubitemid 18033194)
47. Duvanel T, Auckenthaler R, Rohner P, Harms M, Saurat JH. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med 1989; 149:293-6. (Pubitemid 19058512)
48. Chartier C, Grosshans E. Erysipelas. Int J Dermatol 1990; 29:459-67. (Pubitemid 20293306)
49. Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC, Holm SE. Erysipelas: Clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis. 1996; 23:1091-8. (Pubitemid 26367499)
50. Jeng A, Beheshti M, Li J, Nathan R. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: A prospective investigation. Medicine (Baltimore) 2010; 89:217-26.
51. Bernard P, Toty L, Mounier M, Denis F, Bonnetblanc JM. Early detection of streptococcal group antigens in skin samples by latex particle agglutination. Arch Dermatol 1987; 123:468-70. (Pubitemid 17050333)
52. Bernard P, Bedane C, Mounier M, Denis F, Catanzano G, Bonnetblanc JM. Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique. Arch Dermatol 1989; 125:779-82. (Pubitemid 19161120)
53. Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: Diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis. 1996; 23:1162-4. (Pubitemid 26367507)
54. Baddour LM, Bisno AL. Recurrent cellulitis after coronary bypass surgery. Association with superficial fungal infection in saphenous venectomy limbs. JAMA 1984; 251:1049-52. (Pubitemid 14190698)
55. Eriksson BK. Anal colonization of group G beta-hemolytic streptococci in relapsing erysipelas of the lower extremity. Clin Infect Dis. 1999; 29:1319-20. (Pubitemid 30265659)
56. Jorup-Ronstrom C, Britton S, Gavlevik A, Gunnarsson K, Redman AC. The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 1984; 12:390-4. (Pubitemid 15183520)
57. HepburnMJ, Dooley DP, Skidmore PJ, EllisMW, StarnesWF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164:1669-74. (Pubitemid 39037946)
58. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: Opportunities for antimicrobial stewardship. Clin Infect Dis. 2010; 51:895-903.
59. Pallin DJ, Binder WD, Allen MB, et al. Clinical trial: Comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: A randomized controlled trial. Clin Infect Dis. 2013; 56:1754-62.
60. Dall L, Peterson S, Simmons T, Dall A. Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy. Cutis 2005; 75:177-80. (Pubitemid 40521814)
61. Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: A randomized, double blind, placebo-controlled study. Scand J Infect Dis. 1997; 29:377-82.
62. Bergkvist PI, Sjobeck K. Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: A 1-year follow-up. Scand J Infect Dis. 1998; 30:206-7. (Pubitemid 28389089)
63. McGee S, Hirschmann J. Use of corticosteroids in treating infectious diseases. Arch Intern Med 2008; 168:1034-46. (Pubitemid 351749220)
64. Goettsch WG, Bouwes Bavinck JN, Herings RM. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol 2006; 20:834-9. (Pubitemid 44102917)
65. Jorup-Ronstrom C, Britton S. Recurrent erysipelas: Predisposing factors and costs of prophylaxis. Infection 1987; 15:105-6. (Pubitemid 17051548)
66. McNamara DR, Tleyjeh IM, Berbari EF, et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med 2007; 167:709-15. (Pubitemid 46598464)
67. Lewis SD, Peter GS, Gomez-Marin O, Bisno AL. Risk factors for recurrent lower extremity cellulitis in a U.S. Veterans Medical Center population. Am J Med Sci 2006; 332:304-7. (Pubitemid 46005824)
68. Karppelin M, Siljander T, Vuopio-Varkila J, et al. Factors predisposing to acute and recurrent bacterial non-necrotizing cellulitis in hospitalized patients: A prospective case-control study. Clin Microbiol Infect 2010; 16:729-34.
69. Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/ erysipelas of the lower leg: A series with community follow-up. Br J Dermatol 2006; 155:947-50. (Pubitemid 44564503)
70. Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: Risk factors. J Dtsch Dermatol Ges 2004; 2:89-95. (Pubitemid 38325474)
71. Leclerc S, Teixeira A, Mahe E, Descamps V, Crickx B, Chosidow O. Recurrent erysipelas: 47 cases. Dermatology 2007; 214:52-7. (Pubitemid 46033001)
72. Sjoblom AC, Eriksson B, Jorup-Ronstrom C, Karkkonen K, Lindqvist M. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993; 21:390-3.
73. Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect 1991; 22:37-40.
74. Wang JH, Liu YC, Cheng DL, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis. 1997; 25:685-9.
75. Vignes S, Dupuy A. Recurrence of lymphoedema-Associated cellulitis (erysipelas) under prophylactic antibiotherapy: A retrospective cohort study. J Eur Acad Dermatol Venereol 2006; 20:818-22. (Pubitemid 44102915)
76. Thomas KS, Crook AM, Nunn AJ, et al. Penicillin to prevent recurrent leg cellulitis. N Engl J Med 2013; 368:1695-703.
77. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med 1991; 324:370-6.
78. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999; 20:250-78; quiz 79-80.
79. Gaynes RP, Culver DH, Horan TC, Edwards JR, Richards C, Tolson JS. Surgical site infection (SSI) rates in the United States, 1992-1998: The National Nosocomial Infections Surveillance System basic SSI risk index. Clin Infect Dis. 2001; 33(suppl 2):S69-77. (Pubitemid 32762924)
80. Dellinger EP. Approach to the patient with postoperative fever. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2004.
81. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 1961; 50:161-8.
82. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992; 326:281-6.
83. Stone HH, Haney BB, Kolb LD, Geheber CE, Hooper CA. Prophylactic and preventive antibiotic therapy: Timing, duration and economics. Ann Surg 1979; 189:691-9. (Pubitemid 9210731)
84. Dellinger EP, Gross PA, Barrett TL, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. Infectious Diseases Society of America. Clin Infect Dis. 1994; 18:422-7. (Pubitemid 24086316)
85. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: An advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004; 38:1706-15. (Pubitemid 38781662)
86. McDonald M, Grabsch E, Marshall C, Forbes A. Single-versus multiple-dose antimicrobial prophylaxis for major surgery: A systematic review. Aust N Z J Surg 1998; 68:388-96. (Pubitemid 28253184)
87. Steinberg JP, Braun BI, HellingerWC, et al. Timing of antimicrobial prophylaxis and the risk of surgical site infections: Results from the Trial to Reduce Antimicrobial Prophylaxis Errors. Ann Surg 2009; 250:10-6.
88. van Kasteren ME, Mannien J, Ott A, Kullberg BJ, de Boer AS, Gyssens IC. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: Timely administration is the most important factor. Clin Infect Dis. 2007; 44:921-7. (Pubitemid 46452055)
89. Bartlett P, Reingold AL, Graham DR, et al. Toxic shock syndrome associated with surgical wound infections. JAMA 1982; 247: 1448-50. (Pubitemid 12175732)
90. Raab MG, O'Brien M, Hayes JM, Graham DR. Postoperative toxic shock syndrome. Am J Orthop (Belle Mead NJ) 1995; 24:130-6.
91. Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995.
92. Cruse PJE. Wound infections: Epidemiology and clinical characteristics. CT: Appleton & Lange, 1988.
93. Lee J. Surgical wound infections: Surveillance for quality improvement. Boston: Little, Brown and Company, 1995.
94. DeLucia A, Magee JC, Shanley CJ, Simeone DM, Sussman JJ, Wahl WL. Review for surgery: Scientific principles and practice. Philadelphia: J.B. Lippincott Company, 1993.
95. Townsend CMJ, Beuchamp RD, Evers BM, Mattox KL, Sabiston S. The biologic basis of modern surgical practice. Philadelphia:W.B. Saunders and Company, 2001.
96. Dellinger EP, Evans HL, Van Eaton EG. Hospital Infections Chapter 817. In: Ashley SW, Cance WG, Chen H, Jurkovich GJ, Napolitano LM, Pemberton JH, Riall TS, Swanson JS, Valentine JS, eds. Decker, Ontario, CA: ACS Surgery Online, 2012; 8-26.
97. Dellinger EP. Surgical infections and choice of antibiotics. In: Towsend CM, Beauchamp RD, Evers BM, Mattox K, eds. The Biologic basis for modern surgical practice. Sabiston Textbook of surgery, 16th edition, Philadelphia: WB Saunders Co, 2001; 171-88.
98. Howard R, Simmons RL.Wound infections: Epidemiology and clinical characteristics. Surgical infectious diseases. 2nd ed. CT: Appleton & Lange, 1988.
99. Huizinga WK, Kritzinger NA, Bhamjee A. The value of adjuvant systemic antibiotic therapy in localised wound infections among hospital patients: A comparative study. J Infect 1986; 13:11-6. (Pubitemid 16100867)
100. Meislin HW, Lerner SA, Graves MH, et al. Cutaneous abscesses. Anaerobic and aerobic bacteriology and outpatient management. Ann Intern Med 1977; 87:145-9. (Pubitemid 8165576)
101. Paydar KZ, Hansen SL, Charlebois ED, Harris HW, Young DM. Inappropriate antibiotic use in soft tissue infections. Arch Surg 2006; 141:850-4; discussion 55-6. (Pubitemid 44414426)
102. Bobrow BJ, Pollack CV Jr, Gamble S, Seligson RA. Incision and drainage of cutaneous abscesses is not associated with bacteremia in afebrile adults. Ann Emerg Med. 1997; 29:404-8. (Pubitemid 27106700)
103. Brook I, Frazier EH. Aerobic and anaerobic bacteriology of wounds and cutaneous abscesses. Arch Surg 1990; 125:1445-51. (Pubitemid 20375707)
104. Meislin HW. Pathogen identification of abscesses and cellulitis. Ann Emerg Med. 1986; 15:329-32. (Pubitemid 16134843)
105. Dellinger EP. Postoperative wound infection. 2nd ed. Philadelphia: Mosby Year Book, 2001.
106. Wyrick WJ Jr, Rea WJ, McClelland RN. Rare complications with intravenous hyperosmotic alimentation. JAMA 1970; 211:1697-8.
107. Giuliano A, Lewis F Jr, Hadley K, Blaisdell FW. Bacteriology of necrotizing fasciitis. Am J Surg 1977; 134:52-7. (Pubitemid 8148522)
108. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-Associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445-53. (Pubitemid 40471452)
109. Stevens DL, Tanner MH,Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1-7. (Pubitemid 19170377)
110. Chelsom J, Halstensen A, Haga T, Hoiby EA. Necrotising fasciitis due to group A streptococci in western Norway: Incidence and clinical features. Lancet 1994; 344:1111-5. (Pubitemid 24317630)
111. Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: Diagnosis and management. Clin Infect Dis. 2007; 44:705-10.
112. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis. J. 1999; 18:1096-100.
113. Mulla ZD, Leaverton PE, Wiersma ST. Invasive group A streptococcal infections in Florida. South Med J 2003; 96:968-73. (Pubitemid 38281664)
114. Tanz RR, Shulman ST, Shortridge VD, et al. Community-based surveillance in the united states of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons. Clin Infect Dis. 2004; 39:1794-801. (Pubitemid 39657259)
115. Ardanuy C, Domenech A, Rolo D, et al. Molecular characterization of macrolide-And multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993-2008). J Antimicrob Chemother 2010; 65:634-43.
116. Noels H, Weber C. Catching up with important players in atherosclerosis: Type I interferons and neutrophils. Curr Opin Lipidol 2011; 22:144-5.
117. Jaggi P, Beall B, Rippe J, Tanz RR, Shulman ST. Macrolide resistance and emm type distribution of invasive pediatric group A streptococcal isolates: Three-year prospective surveillance from a children's hospital. Pediatr Infect Dis. J. 2007; 26:253-5. (Pubitemid 46340774)
118. Stevens DL. Dilemmas in the treatment of invasive Streptococcus pyogenes infections. Clin Infect Dis. 2003; 37:341-3. (Pubitemid 36976490)
119. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-A comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis. 1999; 28:800-7. (Pubitemid 29169419)
120. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003; 37:333-40. (Pubitemid 36976489)
121. Laucks SS 2nd. Fournier's gangrene. Surg Clin North Am 1994; 74:1339-52. (Pubitemid 24377912)
122. Eke N, Echem RC, Elenwo SN. Fournier's gangrene in Nigeria: A review of 21 consecutive patients. Int Surg 2000; 85:77-81.
123. Sissolak D, Weir WR. Tropical pyomyositis. J Infect 1994; 29:121-7. (Pubitemid 24294721)
124. Pannaraj PS, Hulten KG, Gonzalez BE, Mason EO Jr, Kaplan SL. Infective pyomyositis and myositis in children in the era of communityacquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2006; 43:953-60. (Pubitemid 44631092)
125. Gafur OA, Copley LA, Hollmig ST, Browne RH, Thornton LA, Crawford SE. The impact of the current epidemiology of pediatric musculoskeletal infection on evaluation and treatment guidelines. J Pediatr Orthop 2008; 28:777-85.
126. Crum NF. Bacterial pyomyositis in the United States. Am J Med 2004; 117:420-8. (Pubitemid 39369547)
127. Garcia-Lechuz JM, Cuevas O, Castellares C, Perez-Fernandez C, Cercenado E, Bouza E. Streptococcus pneumoniae skin and soft tissue infections: Characterization of causative strains and clinical illness. Eur J Clin Microbiol Infect Dis. 2007; 26:247-53. (Pubitemid 46572032)
128. Theodorou SJ, Theodorou DJ, Resnick D. MR imaging findings of pyogenic bacterial myositis (pyomyositis) in patients with local muscle trauma: Illustrative cases. Emerg Radiol 2007; 14:89-96. (Pubitemid 46675662)
129. Turecki MB, Taljanovic MS, Stubbs AY, et al. Imaging of musculoskeletal soft tissue infections. Skeletal Radiol 2010; 39:957-71.
130. Browne LP, Mason EO, Kaplan SL, Cassady CI, Krishnamurthy R, Guillerman RP. Optimal imaging strategy for community-Acquired Staphylococcus aureus musculoskeletal infections in children. Pediatr Radiol 2008; 38:841-7.
131. Lin MY, Rezai K, Schwartz DN. Septic pulmonary emboli and bacteremia associated with deep tissue infections caused by community-Acquired methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2008; 46:1553-5. (Pubitemid 351563617)
132. Campbell KM, Vaughn AF, Russell KL, et al. Risk factors for community-Associated methicillin-resistant Staphylococcus aureus infections in an outbreak of disease among military trainees in San Diego, California, in 2002. J Clin Microbiol 2004; 42:4050-3. (Pubitemid 39296122)
133. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-6. (Pubitemid 40734452)
134. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004; 38: 1673-81. (Pubitemid 38781657)
135. File TM, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trials and clinical safety. Clin Infect Dis. 2012; (suppl 3):S173-80.
136. Stevens DL, Aldape MJ, Bryant AE. Life-threatening clostridial infections. Anaerobe 2012; 18:254-9.
137. Stevens DL, Laine BM, Mitten JE. Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens. Antimicrob Agents Chemother 1987; 31:312-6. (Pubitemid 17011258)
138. Stevens DL, Maier KA, Laine BM, Mitten JE. Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens. J Infect Dis. 1987; 155:220-8. (Pubitemid 17022861)
139. Heimbach D. Use of hyperbaric oxygen. Clin Infect Dis. 1993; 17:239-40.
140. Goldstein EJ, Citron DM, Finegold SM. Dog bite wounds and infection: A prospective clinical study. Ann Emerg Med. 1980; 9:508-12. (Pubitemid 11245867)
141. Goldstein EJ, Citron DM. Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds. Antimicrob Agents Chemother 1988; 32:1143-8.
142. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-48.
143. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell K, Fernandez H. Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. J Antimicrob Chemother 2001; 48:641-51. (Pubitemid 33100310)
144. Brakenbury PH, Muwanga C. A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites. Arch Emerg Med 1989; 6:251-6. (Pubitemid 20085181)
145. Talan DA, Abrahamian FM, Moran GJ, Citron DM, Tan JO, Goldstein EJ. Clinical presentation and bacteriologic analysis of infected human bites in patients presenting to emergency departments. Clin Infect Dis. 2003; 37:1481-9. (Pubitemid 37494676)
146. Pascual FB, McGinley EL, Zanardi LR, Cortese MM, Murphy TV. Tetanus surveillance-United States, 1998-2000. MMWR Surveill Summ 2003; 52:1-8.
147. Goldstein EJ. Bite wounds and infection. Clin Infect Dis. 1992; 14:633-8.
148. Gouin S, Patel H. Office management of minor wounds. Can Fam Physician 2001; 47:769-74.
149. Callaham M. Prophylactic antibiotics in common dog bite wounds: A controlled study. Ann Emerg Med. 1980; 9:410-4. (Pubitemid 10020348)
150. Elenbaas RM, McNabney WK, RobinsonWA. Prophylactic oxacillin in dog bite wounds. Ann Emerg Med. 1982; 11:248-51. (Pubitemid 12068529)
151. Dire DJ, Hogan DE, Walker JS. Prophylactic oral antibiotics for lowrisk dog bite wounds. Pediatr Emerg Care 1992; 8:194-9.
152. Dire DJ. Emergency management of dog and cat bite wounds. Emerg Med Clin North Am 1992; 10:719-36.
153. Cummings P. Antibiotics to prevent infection in patients with dog bite wounds: A meta-Analysis of randomized trials. Ann Emerg Med. 1994; 23:535-40. (Pubitemid 24097662)
154. Singer AJ, Dagum AB. Current management of acute cutaneous wounds. N Engl J Med 2008; 359:1037-46.
155. Medeiros I, Saconato H. Antibiotic prophylaxis for mammalian bites. Cochrane Database Syst Rev. 2001:CD001738.
156. Goldstein EJ, Citron DM, Wield B, et al. Bacteriology of human and animal bite wounds. J Clin Microbiol 1978; 8:667-72. (Pubitemid 9073785)
157. Abrahamian FM, Goldstein EJ. Microbiology of animal bite wound infections. Clin Microbiol Rev 2011; 24:231-46.
158. Goldstein EJ, Citron DM, Richwald GA. Lack of in vitro efficacy of oral forms of certain cephalosporins, erythromycin, and oxacillin against Pasteurella multocida. Antimicrob Agents Chemother 1988; 32:213-5. (Pubitemid 18061377)
159. Goldstein EJ, Citron DM, Merriam CV. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother 1999; 43:1469-74. (Pubitemid 29259346)
160. Stevens DL, Higbee JW, Oberhofer TR, Everett ED. Antibiotic susceptibilities of human isolates of Pasteurella multocida. Antimicrob Agents Chemother 1979; 16:322-4. (Pubitemid 10224024)
161. No authors listed.] Diphtheria, tetanus, and pertussis: Recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40:1-28.
162. Bowie C. Tetanus toxoid for adults-too much of a good thing. Lancet 1996; 348:1185-6. (Pubitemid 26361600)
163. Zook EG, Miller M, Van Beek AL,Wavak P. Successful treatment protocol for canine fang injuries. J Trauma 1980; 20:243-7. (Pubitemid 10134443)
164. Schultz RC, McMaster WC. The treatment of dog bite injuries, especially those of the face. Plast Reconstr Surg 1972; 49:494-500.
165. Stucker FJ, Shaw GY, Boyd S, Shockley WW. Management of animal and human bites in the head and neck. Arch Otolaryngol Head Neck Surg 1990; 116:789-93. (Pubitemid 20218754)
166. Palmer J, Rees M. Dog bites of the face: A 15 year review. Br J Plast Surg 1983; 36:315-8. (Pubitemid 13046576)
167. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281:1735-45. (Pubitemid 29226485)
168. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341:815-26. (Pubitemid 29420478)
169. No authors listed.] Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50:909-19.
170. Bass JW, Freitas BC, Freitas AD, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis. J. 1998; 17:447-52. (Pubitemid 28287606)
171. Ramirez Ramirez CR, Saavedra S, Ramirez Ronda CH. Bacillary angiomatosis: Microbiology, histopathology, clinical presentation, diagnosis and management. Bol Asoc Med P R 1996; 88:46-51.
172. Andrychowski J, Jasielski P, Netczuk T, Czernicki Z. Empyema in spinal canal in thoracic region, abscesses in paravertebral space, spondylitis: In clinical course of zoonosis Erysipelothrix rhusiopathiae. Eur Spine J 2012; 21(suppl 4):557-63.
173. Brooke CJ, Riley TV. Erysipelothrix rhusiopathiae: Bacteriology, epidemiology and clinical manifestations of an occupational pathogen. J Med Microbiol 1999; 48:789-99. (Pubitemid 29476413)
174. Estes DM, Dow SW, Schweizer HP, Torres AG. Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther 2010; 8:325-38.
175. Srinivasan A, Kraus CN, DeShazer D, et al. Glanders in a military research microbiologist. N Engl J Med 2001; 345:256-8. (Pubitemid 32695065)
176. Perry RD, Fetherston JD. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 1997; 10:35-66.
177. Maurin M, Pelloux I, Brion JP, Del Bano JN, Picard A. Human tularemia in France, 2006-2010. Clin Infect Dis. 2011; 53:e133-41.
178. Kroshinsky D, Grossman ME, Fox LP. Approach to the patient with presumed cellulitis. Semin Cutan Med Surg 2007; 26:168-78. (Pubitemid 350216509)
179. Lopez FA, Sanders CV. Dermatologic infections in the immunocompromised (non-HIV) host. Infect Dis. Clin North Am 2001; 15:671-702, xi. (Pubitemid 32606918)
180. Pizzo PA. Fever in immunocompromised patients. N Engl J Med 1999; 341:893-900. (Pubitemid 29427053)
181. Podjasek JO, Wetter DA, Pittelkow MR, Wada DA. Cutaneous smallvessel vasculitis associated with solid organ malignancies: The Mayo Clinic experience, 1996 to 2009. J Am Acad Dermatol 2012; 66: E55-65.
182. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012; 1:CD004386.
183. Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis. 2001; 33:629-40. (Pubitemid 32762936)
184. Lamoth F, Jaton K, Prod'hom G, et al. Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia. J Clin Microbiol 2010; 48:3510-6.
185. Petti CA. Detection and identification of microorganisms by gene amplification and sequencing. Clin Infect Dis. 2007; 44:1108-14. (Pubitemid 46580283)
186. Schuetz AN. Invasive fungal infections: Biomarkers and molecular approaches to diagnosis. Clin Lab Med 2013; 33:505-25.
187. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011; 52:e56-93.
188. Lingaratnam S, Slavin MA, Koczwara B, et al. Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011; 41:75-81.
189. Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6:122-74. (Pubitemid 351340523)
190. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: A global perspective. Preface. Bone Marrow Transplant 2009; 44:453-5.
191. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46:327-60. (Pubitemid 351265310)
192. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48:503-35.
193. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49:1-45.
194. Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012; 40:43-9.
195. Paesmans M, Klastersky J, Maertens J, et al. Predicting febrile neutropenic patients at low risk using the MASCC score: Does bacteremia matter? Support Care Cancer 2011; 19:1001-8.
196. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006; 24:4129-34. (Pubitemid 46622289)
197. Lanoix JP, Schmit JL, Douadi Y. Bacterial lung sepsis in patients with febrile neutropenia. Curr Opin Pulm Med 2012; 18:175-80.
198. Mebis J, Jansens H, Minalu G, et al. Long-term epidemiology of bacterial susceptibility profiles in adults suffering from febrile neutropenia with hematologic malignancy after antibiotic change. Infect Drug Resist 2010; 3:53-61.
199. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009; 9:228-36.
200. Johnston DL, Waldhausen JH, Park JR. Deep soft tissue infections in the neutropenic pediatric oncology patient. J Pediatr Hematol Oncol 2001; 23:443-7. (Pubitemid 33031773)
201. Reich HL, Williams Fadeyi D, Naik NS, Honig PJ, Yan AC. Nonpseudomonal ecthyma gangrenosum. J Am Acad Dermatol 2004; 50: S114-7. (Pubitemid 38580537)
202. Wade JC. Viral infections in patients with hematological malignancies. Hematology Am Soc Hematol Educ Program 2006; 2006:368-74.
203. Pizzo PA. Management of fever in patients with cancer and treatmentinduced neutropenia. N Engl J Med 1993; 328:1323-32.
204. Kosmidis CI, Chandrasekar PH. Management of gram-positive bacterial infections in patients with cancer. Leuk Lymphoma 2012; 53:8-18.
205. Tattevin P, Camus C. What can we learn from studies comparing linezolid with vancomycin in neutropenic patients when vancomycin dosages are not optimized? Clin Infect Dis. 2006; 42:1813-4; author reply 14-5. (Pubitemid 43839459)
206. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006; 42:597-607. (Pubitemid 43271371)
207. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341:305-11. (Pubitemid 29350300)
208. Freifeld AG, Sepkowitz KA. No place like home? Outpatient management of patients with febrile neutropenia and low risk. J Clin Oncol 2011; 29:3952-4.
209. Spellberg B, Ibrahim A, Roilides E, et al. Combination therapy for mucormycosis: Why, what, and how? Clin Infect Dis. 2012; 54(suppl 1): S73-8.
210. Wingard JR, Santos GW, Saral R. Differences between first and subsequent fevers during prolonged neutropenia. Cancer 1987; 59:844-9. (Pubitemid 17018768)
211. Wade JC. Management of infection in patients with acute leukemia. Hematol Oncol Clin North Am 1993; 7:293-315. (Pubitemid 23052984)
212. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev. 2008; 4:CD007394.
213. Maertens J, Theunissen K, Lodewyck T, Lagrou K, Van Eldere J. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007; 50(suppl 1):2-17. (Pubitemid 46501739)
214. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis. 2007; 44:402-9. (Pubitemid 46147624)
215. Mays SR, Bogle MA, Bodey GP. Cutaneous fungal infections in the oncology patient: Recognition and management. AmJ Clin Dermatol 2006; 7:31-43.
216. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis. 1991; 164:731-40.
217. Bodey GP, Luna M. Skin lesions associated with disseminated candidiasis. JAMA 1974; 229:1466-8.
218. Wingard JR, Merz WG, Saral R. Candida tropicalis: A major pathogen in immunocompromised patients. Ann Intern Med 1979; 91:539-43. (Pubitemid 10188849)
219. Jarowski CI, Fialk MA, Murray HW, et al. Fever, rash, and muscle tenderness. A distinctive clinical presentation of disseminated candidiasis. Arch Intern Med 1978; 138:544-6. (Pubitemid 9032863)
220. Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine 1986; 65:268-79. (Pubitemid 16049283)
221. Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 1987; 317:1105-8. (Pubitemid 17156739)
222. Petrikkos G, Skiada A, Lortholary O, Roilides E,Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012; 54(suppl 1):S23-34.
223. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010; 50:1091-100.
224. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: A 10-year study. Clin Infect Dis. 2000; 31:188-9. (Pubitemid 32268963)
225. Gartenberg G, Bottone EJ, Keusch GT,Weitzman I. Hospital-Acquired mucormycosis (Rhizopus rhizopodiformis) of skin and subcutaneous tissue: Epidemiology, mycology and treatment. N Engl J Med 1978; 299:1115-8. (Pubitemid 9058350)
226. Anaissie E. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review. Clin Infect Dis. 1992; 14 (suppl 1):S43-53.
227. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695-704. (Pubitemid 47623773)
228. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis. 2004; 38:1428-39. (Pubitemid 38678611)
229. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
230. Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 2010; 38:89-97.
231. Thomas LM, Rand HK, Miller JL, Boyd AS. Primary cutaneous aspergillosis in a patient with a solid organ transplant: Case report and review of the literature. Cutis 2008; 81:127-30.
232. Shinohara MM, George E. Scedosporium apiospermum: An emerging opportunistic pathogen thatmust be distinguished fromAspergillus and other hyalohyphomycetes. J Cutan Pathol 2009; 36(suppl 1):39-41.
233. Miyamoto H, Hayashi H, Nakajima H. Cutaneous mucormycosis in a patient with acute lymphocytic leukemia. J Dermatol 2005; 32:273-7. (Pubitemid 40745761)
234. Halpern M, Balbi E, Carius L, et al. Cellulitis and nodular skin lesions due to Fusarium spp in liver transplant: Case report. Transplant Proc 2010; 42:599-600.
235. Abuav R, McGirt LY, Kazin RA. Cryptococcal panniculitis in an immunocompromised patient: A case report and review of the literature. Cutis 2010; 85:303-6.
236. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010; 50: 291-322.
237. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007; 45:807-25. (Pubitemid 47580372)
238. Freifeld AG, Wheat LJ, Kaul DR. Histoplasmosis in solid organ transplant recipients: Early diagnosis and treatment. Curr Opin Organ Transplant 2009; 14:601-5.
239. Shiley K, Blumberg E. Herpes viruses in transplant recipients: HSV, VZV, human herpes viruses, and EBV. Infect Dis. Clin North Am 2010; 24:373-93.
240. Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: No evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110:3071-7. (Pubitemid 350006963)
241. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of longterm suppressive acyclovir after hematopoietic stem-cell transplantation: Impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis. 2007; 196:266-70. (Pubitemid 47047466)
242. Basile A, Simzar S, Bentow J, et al. Dis.seminated Strongyloides stercoralis: Hyperinfection during medical immunosuppression. J Am Acad Dermatol 2010; 63:896-902.
243. Walia R, Montoya JG, Visvesvera GS, Booton GC, Doyle RL. A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient. Transpl Infect Dis. 2007; 9:51-4.
244. Godoy HL, Guerra CM, Viegas RF, et al. Infections in heart transplant recipients in Brazil: The challenge of Chagas' disease. J Heart Lung Transplant 2010; 29:286-90.
245. Sandhu K, Gupta S, Kumar B, Dhandha R, Udigiri NK, Minz M. The pattern of mucocutaneous infections and infestations in renal transplant recipients. J Dermatol 2003; 30:590-5. (Pubitemid 37071281)
246. Pickering LK. Committee on Infectious Diseases, American Academy of Pediatrics. Antimicrobial agents and related therapy. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003.
247. Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis. 2012; 55:381-90.